Jen-Jane Liu, MD, Oregon Health and Science University, Portland, OR, provides an overview of up and coming novel therapeutics in kidney cancer. So far, kidney cancer has gained approval of treatments within immunotherapy and tyrosine kinase inhibitors (TKIs). This is in contrast to prostate cancer that has shown success in the continual manipulation of the same hormonal axis, and bladder cancer, where chemotherapy has been the standard of care for many years until recently with the development of targeted therapies. Dr Liu highlights the need of establishing quality biomarker testing within the field of kidney cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.
